Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose or AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 in adult
participants with familial chylomicronemia syndrome (FCS). Participants who have met all
protocol eligibility criteria will be randomized to receive 4 total doses of ARO-APOC3 or
matching placebo administered subcutaneously.